Comparative Study of The Safety and Efficacy of Different Anticoagulation Regimens in Patients with Atrial Fibrillation Undergoing Coronary Artery Bypass Grafting

Abstract

Atrial fibrillation (AF) is common in patients after coronary artery bypass grafting (CABG), and anticoagulant treatment is crucial to avoiding thromboembolic consequences. to assess the efficacy and safety of several anticoagulation therapies, such as warfarin, low molecular weight heparin (LMWH), unfractionated heparin (UFH), and novel oral anticoagulants (NOACs), in AF patients undergoing CABG. Patients with AF receiving CABG at a tertiary care facility were included in this retrospective cohort research. Based on their anticoagulant protocol, the patients were split up into four groups. The groups were compared for safety outcomes (thromboembolic events, bleeding complications) and efficacy outcomes (myocardial infarction, stroke, and mortality). The study involved 100 patients in total. The findings demonstrated that, in comparison to warfarin, NOACs were linked to a decreased risk of bleeding problems (p<0.01). The safety profiles of UFH and LMWH were comparable. The four groups' efficacy results were comparable. According to this study, NOACs might be a safer option for AF patients having CABG than warfarin. To validate these results and assess the cost-effectiveness of various anticoagulation regimens, more research is required.